Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Anus Neoplasms 1

Interventions

pembrolizumab 33Cetuximab 16Cisplatin 10Radiotherapy 8Paclitaxel 8Docetaxel 8atezolizumab 7Fluorouracil 7cemiplimab 6Drug Therapy 6budigalimab 5Gemcitabine 5Cyclophosphamide 5Blood Specimen Collection 5trametinib 4Pemetrexed 4Nivolumab 4Magnetic Resonance Spectroscopy 4Bleomycin 4Bevacizumab 4palbociclib 3fludarabine 3durvalumab 3dabrafenib 3avelumab 3Trastuzumab 3Oxaliplatin 3Interleukin-2 3Indocyanine Green 3Immunotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × prexasertib × Head & Neck × Clear all
NCT02555644 2019-02-15

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Eli Lilly and Company

Phase 1 Completed
70 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡